Evidence map›Paper›PMID 31638431›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019

p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin.

Aminah A Loonat, E Denise Martin, Negin Sarafraz-Shekary, Katharina Tilgner, Nicholas T Hertz, Rebecca Levin, Kevan M Shokat, Alma L Burlingame, Pelin Arabacilar, Shahzan Uddin and 3 more

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.International journal of molecular sciences · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Aminah A LoonatSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
E Denise MartinSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Negin Sarafraz-ShekarySchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Katharina TilgnerSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Nicholas T HertzUniversity of California-San Francisco, San Francisco, California, USA.
Rebecca LevinUniversity of California-San Francisco, San Francisco, California, USA.
Kevan M ShokatUniversity of California-San Francisco, San Francisco, California, USA.
Alma L BurlingameUniversity of California-San Francisco, San Francisco, California, USA.
Pelin ArabacilarSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Shahzan UddinSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Max ThomasSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
Michael S MarberSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
James E ClarkSchool of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King's College London, London, United Kingdom.
King's College London · GBUniversity of California, San Francisco · USBritish Heart Foundation · GB

Funding

Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Biotechnology and Biological Sciences Research CouncilBritish Heart Foundation SP/14/2/30922Medical Research Council MR/J007501/1NIGMS NIH HHS P41 GM103481
6 · The paper itself

Abstract

Despite the high and preferential expression of p38γ MAPK in the myocardium, little is known about its function in the heart. The aim of the current study was to elucidate the physiologic and biochemical roles of p38γ in the heart. Expression and subcellular localization of p38 isoforms was determined in mouse hearts. Comparisons of the cardiac function and structure of wild-type and p38γ knockout (KO) mice at baseline and after abdominal aortic banding demonstrated that KO mice developed less ventricular hypertrophy and that contractile function is better preserved. To identify potential substrates of p38γ, we generated an analog-sensitive mutant to affinity tag endogenous myocardial proteins. Among other proteins, this technique identified calpastatin as a direct p38γ substrate. Moreover, phosphorylation of calpastatin by p38γ impaired its ability to inhibit the protease, calpain. We have identified p38γ as an important determinant of the progression of pathologic cardiac hypertrophy after aortic banding in mice. In addition, we have identified calpastatin, among other substrates, as a novel direct target of p38γ that may contribute to the protection observed in p38γKO mice.-Loonat, A. A., Martin, E. D., Sarafraz-Shekary, N., Tilgner, K., Hertz, N. T., Levin, R., Shokat, K. M., Burlingame, A. L., Arabacilar, P., Uddin, S., Thomas, M., Marber, M. S., Clark, J. E. p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin.

Indexed as

AnimalsCalcium-Binding ProteinsCalpainEchocardiographyElectrophoresis, Polyacrylamide GelHEK293 CellsHumansImmunohistochemistryMaleMiceMitogen-Activated Protein Kinase 12p38 Mitogen-Activated Protein KinasesPhosphorylationProtein IsoformsTandem Mass SpectrometryVentricular RemodelingCalcium-Binding ProteinsCalpaincalpastatinMitogen-Activated Protein Kinase 12p38 Mitogen-Activated Protein KinasesProtein Isoformsfailurehearthypertrophykinaseprotection

Identifiers

PMID31638431
PMCPMC6894093
OpenAlexW2888566371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.